| 10.13 0.06 (0.6%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.55 | 1-year : | 14.66 |
| Resists | First : | 10.75 | Second : | 12.55 |
| Pivot price | 9.79  |
|||
| Supports | First : | 9.46 | Second : | 8.67 |
| MAs | MA(5) : | 9.93 |
MA(20) : | 9.68 |
| MA(100) : | 9.62 |
MA(250) : | 13.02 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 48.9 |
D(3) : | 49 |
| RSI | RSI(14): 63.4 |
|||
| 52-week | High : | 18.37 | Low : | 7.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANIK ] has closed above the upper band by 3.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.18 - 10.22 | 10.22 - 10.26 |
| Low: | 9.79 - 9.83 | 9.83 - 9.88 |
| Close: | 10.05 - 10.13 | 10.13 - 10.2 |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Thu, 06 Nov 2025
Anika Therapeutics Inc (ANIK) Q3 2025 Earnings Call Highlights: Strong Growth in Regenerative ... - Yahoo Finance
Thu, 06 Nov 2025
Anika Therapeutics (ANIK) Rating Maintained, Price Target Raised by Barrington Research | ANIK Stock News - GuruFocus
Thu, 06 Nov 2025
Anika Therapeutics Files Final Module for Hyalofast - MSN
Thu, 06 Nov 2025
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2025 Earnings Call Transcript - Insider Monkey
Wed, 05 Nov 2025
Anika Therapeutics (ANIK): Losses Narrow 6.5% Annually, but Guidance Continues to Undercut Bullish Narratives - simplywall.st
Wed, 05 Nov 2025
Anika Therapeutics (ANIK) Trades Below Fair Value; Valuation Discount Reinforces Cautious Market Narratives - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 14 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 4.8 (%) |
| Held by Institutions | 89.4 (%) |
| Shares Short | 308 (K) |
| Shares Short P.Month | 360 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.23 |
| Profit Margin | -53 % |
| Operating Margin | -14.9 % |
| Return on Assets (ttm) | -2.5 % |
| Return on Equity (ttm) | -7.3 % |
| Qtrly Rev. Growth | -8.2 % |
| Gross Profit (p.s.) | 4.58 |
| Sales Per Share | 7.94 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | 41 (M) |
| PE Ratio | -11.26 |
| PEG Ratio | 0 |
| Price to Book value | 0.98 |
| Price to Sales | 1.27 |
| Price to Cash Flow | 23.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|